Vestal Point Capital, LP
CIK 1974915 · View on SEC EDGAR ↗
- Portfolio value
- $4.3B
- Positions
- 68
- As of
- June 30, 2026
#897 of 9,443 by 13F value · top 9.5%
Portfolio value QoQ: +19.6% 13F does not disclose cash
- Top 10 holdings weight
- 50.29%
- Top 25 holdings weight
- 80.28%
- Positions above 1%
- 29
- Effective number of positions
- 27.4
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 39.4% Est. buys $1,600,614,478 · sells $1,547,505,051
Median holding: 2.5 quarters Tracked Q4 2024–Q2 2026 · 37.8% still held
- New positions
- 11
- Increased
- 31
- Decreased
- 21
- Closed
- 33
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +68.0% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.8% · Options excluded: 1.6%
Sector breakdown
Healthcare
96.5%
Other/Unmapped
3.5%
Full portfolio 68 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. - Common Stock | $344,750,500 | 8.06% | 6,025,000 | $142,798,750 | Up ×4 | ||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $316,845,800 | 7.40% | 1,880,000 | $152,170,800 | Up ×1 | ||
| ABVX Abivax SA - American Depositary Shares | $313,086,774 | 7.32% | 2,349,443 | $146,061,774 | Up ×1 | ||
| UTHR United Therapeutics Corporation - Common Stock | $235,696,050 | 5.51% | 435,000 | $191,222,550 | Up ×1 | ||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $203,000,000 | 4.74% | 4,000,000 | $75,600,000 | Up ×1 | ||
| NRIX Nurix Therapeutics, Inc. - Common stock | $195,293,000 | 4.56% | 8,050,000 | $94,543,000 | Up ×6 | ||
| BCAX Bicara Therapeutics Inc. - Common Stock | $155,872,500 | 3.64% | 5,250,000 | $47,969,250 | Down ×1 | ||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $132,216,150 | 3.09% | 19,415,000 | $51,756,150 | Up ×4 | ||
| ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | $128,378,250 | 3.00% | 1,575,000 | $-14,264,250 | Down ×1 | ||
| ABT Abbott Laboratories Common Stock | $127,036,000 | 2.97% | 1,400,000 | ||||
| ZBH Zimmer Biomet Holdings, Inc. Common Stock | $120,526,000 | 2.82% | 1,400,000 | $103,346,200 | Up ×2 | ||
| IRON Disc Medicine, Inc. - Common Stock | $113,367,000 | 2.65% | 1,550,000 | $68,609,000 | Up ×1 | ||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $111,320,000 | 2.60% | 4,600,000 | $52,043,001 | Up ×2 | ||
| PODD Insulet Corporation - Common Stock | $102,007,500 | 2.38% | 670,000 | $91,389,386 | Up ×1 | ||
| Unknown issuer (CUSIP: K08588103) | $100,020,000 | 2.34% | 375,000 | Up ×1 | |||
| AZN AstraZeneca PLC - American Depositary Shares | $85,329,000 | 1.99% | 450,000 | $65,607,000 | Up ×1 | ||
| SNY Sanofi - American Depositary Shares | $85,320,000 | 1.99% | 2,000,000 | $17,868,000 | Up ×1 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $84,276,000 | 1.97% | 450,000 | $-146,692,750 | Down ×1 | ||
| BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | $83,000,000 | 1.94% | 8,300,000 | $16,122,000 | Up ×2 | ||
| DYN Dyne Therapeutics, Inc. - Common Stock | $74,958,750 | 1.75% | 3,375,000 | $2,438,750 | Down ×1 | ||
| NKTR Nektar Therapeutics - Common Stock | $69,810,000 | 1.63% | 1,000,000 | $49,304,250 | Up ×1 | ||
| GMED Globus Medical, Inc. Class A Common Stock | $67,158,500 | 1.57% | 850,000 | $14,556,097 | Up ×1 | ||
| TARS Tarsus Pharmaceuticals, Inc. - Common Stock | $66,087,000 | 1.54% | 1,050,000 | $52,057,000 | Up ×1 | ||
| IMTX Immatics N.V. - Ordinary Shares | $62,552,750 | 1.46% | 6,175,000 | $1,790,750 | |||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $57,815,000 | 1.35% | 3,100,000 | $31,968,607 | Up ×1 | ||
| IMCR Immunocore Holdings plc - American Depositary Shares | $57,150,000 | 1.34% | 1,800,000 | $-26,271,070 | Down ×1 | ||
| RGEN Repligen Corporation - Common Stock | $54,576,000 | 1.28% | 400,000 | $-54,407,500 | Down ×1 | ||
| BMY Bristol-Myers Squibb Company Common Stock | $46,096,000 | 1.08% | 800,000 | $-14,554,000 | Down ×1 | ||
| QURE uniQure N.V. - Ordinary Shares | $43,066,100 | 1.01% | 935,000 | $37,196,515 | Up ×1 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $42,252,000 | 0.99% | 700,000 | $5,041,815 | Up ×2 | ||
| DRUG Bright Minds Biosciences Inc. - common stock | $38,259,000 | 0.89% | 545,000 | $2,334,483 | Up ×1 | ||
| MDGL Madrigal Pharmaceuticals, Inc. - Common Stock | $34,901,750 | 0.82% | 65,000 | $18,429,196 | Up ×1 | ||
| ALC Alcon Inc. Ordinary Shares | $33,550,000 | 0.78% | 500,000 | $-26,730,000 | Down ×2 | ||
| MYGN Myriad Genetics, Inc. - Common Stock | $32,746,850 | 0.77% | 5,735,000 | $25,330,850 | Up ×3 | ||
| RAPP Rapport Therapeutics, Inc. - Common Stock | $30,419,100 | 0.71% | 730,000 | $-14,520,505 | Down ×1 | ||
| CBIO Crescent Biopharma, Inc. - Common Stock | $29,340,000 | 0.69% | 1,630,000 | $1,785,000 | Up ×1 | ||
| GEHC GE HealthCare Technologies Inc. - Common Stock | $28,804,500 | 0.67% | 450,000 | $11,009,500 | Up ×1 | ||
| INSM Insmed Incorporated - Common Stock | $26,655,000 | 0.62% | 250,000 | ||||
| VKTX Viking Therapeutics, Inc. - Common Stock | $26,526,800 | 0.62% | 680,000 | $-3,219,543 | Down ×1 | ||
| BBNX Beta Bionics, Inc. - Common Stock | $25,072,000 | 0.59% | 1,600,000 | $2,912,590 | Down ×1 | ||
| REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $24,941,600 | 0.58% | 40,000 | $-5,964,000 | |||
| SLDB Solid Biosciences Inc. - Common Stock | $21,578,400 | 0.50% | 2,160,000 | $-14,421,600 | Down ×2 | ||
| ANRO Alto Neuroscience, Inc. Common Stock | $20,716,150 | 0.48% | 785,000 | $-25,684,256 | Down ×2 | ||
| Unknown issuer (CUSIP: 337185102) | $20,381,560 | 0.48% | 1,013,000 | Up ×1 | |||
| LXEO Lexeo Therapeutics, Inc. - Common Stock | $20,109,600 | 0.47% | 4,320,000 | $-5,576,900 | Down ×1 | ||
| SVRA Savara, Inc. - Common Stock | $16,755,200 | 0.39% | 2,720,000 | $2,558,916 | Up ×2 | ||
| GLTO Galecto, Inc. - Common Stock | $14,955,750 | 0.35% | 575,000 | $-584,250 | Down ×1 | ||
| SGP SpyGlass Pharma, Inc. - Common Stock | $14,914,200 | 0.35% | 670,000 | $-2,361,552 | Up ×1 | ||
| TECX Tectonic Therapeutic, Inc. - Common Stock | $14,609,375 | 0.34% | 425,000 | $4,470,895 | Up ×1 | ||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $14,322,000 | 0.33% | 775,000 | Up ×1 | |||
| EVMN Evommune, Inc. Common Stock | $13,290,000 | 0.31% | 1,000,000 | Up ×1 | |||
| Unknown issuer (CUSIP: 482931102) | $12,667,250 | 0.30% | 575,000 | Up ×1 | |||
| AVR Anteris Technologies Global Corp. - Common Stock | $9,948,500 | 0.23% | 1,010,000 | $3,594,971 | Down ×1 | ||
| ZBIO Zenas BioPharma, Inc. - Common Stock | $9,263,700 | 0.22% | 365,000 | $5,353,700 | Up ×1 | ||
| VYGR Voyager Therapeutics, Inc. - Common Stock | $9,187,500 | 0.21% | 2,625,000 | $-2,403,833 | Down ×1 | ||
| OKUR OnKure Therapeutics, Inc. - Class A Common Stock | $8,325,187 | 0.19% | 1,825,699 | $708,336 | Down ×1 | ||
| SRZN Surrozen, Inc. - Common Stock | $7,906,161 | 0.18% | 304,669 | $-1,957,577 | Down ×1 | ||
| MNPR Monopar Therapeutics Inc. - Common Stock | $7,011,563 | 0.16% | 75,727 | $3,427,311 | Up ×1 | ||
| ZURA Zura Bio Limited - Class A Ordinary shares | $6,926,340 | 0.16% | 1,173,956 | $3,885,890 | Up ×1 | ||
| OLMA Olema Pharmaceuticals, Inc. - Common Stock | $5,236,073 | 0.12% | 418,551 | $-1,153,622 | Down ×2 | ||
| PALI Palisade Bio, Inc. - Common Stock | $5,225,000 | 0.12% | 2,500,000 | $850,000 | |||
| IBIO iBio, Inc. - Common Stock | $4,550,000 | 0.11% | 2,600,000 | Up ×1 | |||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $4,139,044 | 0.10% | 535,452 | Up ×1 | |||
| Unknown issuer (CUSIP: 29286X101) | $2,884,654 | 0.07% | 1,667,430 | Up ×1 | |||
| RZLT Rezolute, Inc. - Common Stock (NV) | $1,991,595 | 0.05% | 382,999 | ||||
| NYXH Nyxoah SA - Ordinary Shares | $1,425,449 | 0.03% | 843,461 | $-1,111,041 | Down ×6 | ||
| TENX Tenax Therapeutics, Inc. - Common Stock | $777,537 | 0.02% | 53,439 | $-76,953 | |||
| APRE Aprea Therapeutics, Inc. - Common Stock | $280,805 | 0.01% | 350,000 | $13,790 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| ABT | $127,036,000 | 1,400,000 | 2.97% |
| Unknown issuer (CUSIP: K08588103) | $100,020,000 | 375,000 | 2.34% |
| INSM | $26,655,000 | 250,000 | 0.62% |
| Unknown issuer (CUSIP: 337185102) | $20,381,560 | 1,013,000 | 0.48% |
| AVTX | $14,322,000 | 775,000 | 0.33% |
| EVMN | $13,290,000 | 1,000,000 | 0.31% |
| Unknown issuer (CUSIP: 482931102) | $12,667,250 | 575,000 | 0.30% |
| IBIO | $4,550,000 | 2,600,000 | 0.11% |
| SGMT | $4,139,044 | 535,452 | 0.10% |
| Unknown issuer (CUSIP: 29286X101) | $2,884,654 | 1,667,430 | 0.07% |
| RZLT | $1,991,595 | 382,999 | 0.05% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| NBIX | Bought more | +630K | +$152.2M |
| RVMD | Trimmed | -1.9M | -$146.7M |
| ABVX | Bought more | +849K | +$146.1M |
| BMRN | Bought more | +2.5M | +$142.8M |
| NRIX | Bought more | +1.6M | +$94.5M |
| ELVN | Bought more | +750K | +$75.6M |
| IRON | Bought more | +850K | +$68.6M |
| AZN | Bought more | +350K | +$65.6M |
| RGEN | Trimmed | -525K | -$54.4M |
| TARS | Bought more | +850K | +$52.1M |
3 positions hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| QQQ | March 31, 2026 | 350,000 | $215,008,500 | |
| ACLX | March 31, 2026 | 2,925,000 | $190,710,000 | No longer tracked |
| JAZZ | March 31, 2025 | 975,000 | $120,071,250 | 101.7% |
| APGE | June 30, 2026 | 1,100,000 | $92,587,000 | 1.6% |
| ASND | June 30, 2026 | 375,000 | $85,773,750 | -3.3% |
| DXCM | March 31, 2026 | 1,275,000 | $84,621,750 | 42.4% |
| INSM | June 30, 2025 | 1,075,000 | $82,011,750 | 24.6% |
| MRK | March 31, 2026 | 775,000 | $81,576,500 | 26.1% |
| MRK | March 31, 2025 | 800,000 | $79,584,000 | 69.0% |
| FOLD | Dec. 31, 2025 | 9,750,000 | $76,830,000 | No longer tracked |
| ABT | March 31, 2026 | 600,000 | $75,174,000 | 11.4% |
| IONS | Dec. 31, 2025 | 1,075,000 | $70,326,500 | -24.3% |
| SRRK | June 30, 2026 | 1,324,422 | $65,108,586 | 0.2% |
| BDX | Dec. 31, 2025 | 325,000 | $60,830,250 | 23.7% |
| BMRN | March 31, 2025 | 860,000 | $56,527,800 | -4.3% |
| VERA | June 30, 2026 | 1,368,159 | $55,041,037 | -26.2% |
| TERN | June 30, 2026 | 1,000,000 | $52,720,000 | No longer tracked |
| GEHC | Sept. 30, 2025 | 700,000 | $51,849,000 | -1.4% |
| BSX | June 30, 2026 | 800,000 | $50,200,000 | 15.8% |
| NUVL | June 30, 2026 | 481,715 | $49,351,702 | No longer tracked |
| JAZZ | March 31, 2026 | 290,000 | $49,300,000 | 32.4% |
| DAWN | March 31, 2026 | 5,200,000 | $48,464,000 | No longer tracked |
| SLNO | March 31, 2025 | 1,060,000 | $47,647,000 | No longer tracked |
| COGT | June 30, 2026 | 1,230,888 | $47,376,879 | -6.6% |
| DNTH | Dec. 31, 2025 | 1,180,000 | $46,433,000 | 171.3% |
| CYTK | Dec. 31, 2025 | 725,000 | $39,846,000 | 21.9% |
| CLDX | June 30, 2026 | 1,224,165 | $38,830,514 | 9.1% |
| BIIB | Dec. 31, 2025 | 275,000 | $38,522,000 | 22.5% |
| AXSM | March 31, 2026 | 210,000 | $38,354,400 | 23.4% |
| CDTX | Dec. 31, 2025 | 400,000 | $38,304,000 | No longer tracked |
| KALV | June 30, 2026 | 1,850,000 | $37,240,500 | No longer tracked |
| SNY | March 31, 2025 | 750,000 | $36,172,500 | -17.7% |
| ATXS | Dec. 31, 2025 | 4,956,000 | $36,079,680 | No longer tracked |
| PTGX | June 30, 2026 | 326,159 | $34,377,159 | 23.9% |
| DNLI | June 30, 2026 | 1,773,326 | $34,047,859 | -2.2% |
| GSK | March 31, 2025 | 1,000,000 | $33,820,000 | 33.6% |
| CRNX | Dec. 31, 2025 | 750,000 | $31,237,500 | 82.1% |
| AZN | March 31, 2025 | 475,000 | $31,122,000 | 125.2% |
| WAT | June 30, 2026 | 100,000 | $29,780,000 | 6.1% |
| DHR | Dec. 31, 2025 | 150,000 | $29,739,000 | -6.5% |
| MDGL | March 31, 2025 | 95,000 | $29,314,150 | 56.7% |
| INSP | June 30, 2026 | 539,269 | $27,815,495 | 36.1% |
| MLTX | Sept. 30, 2025 | 550,000 | $25,960,000 | 121.2% |
| COO | Sept. 30, 2025 | 350,000 | $24,906,000 | 10.5% |
| GPCR | Sept. 30, 2025 | 1,200,000 | $24,888,000 | 81.6% |
| SLNO | June 30, 2026 | 730,000 | $24,440,400 | No longer tracked |
| LNTH | March 31, 2026 | 360,000 | $23,958,000 | 32.2% |
| URGN | June 30, 2025 | 2,152,957 | $23,811,704 | 237.6% |
| EW | Sept. 30, 2025 | 300,000 | $23,463,000 | 14.9% |
| BLTE | Dec. 31, 2025 | 312,500 | $23,125,000 | 2.5% |
| ZYME | March 31, 2026 | 865,000 | $22,775,450 | 8.0% |
| RARE | Dec. 31, 2025 | 750,000 | $22,560,000 | 13.6% |
| COGT | Sept. 30, 2025 | 3,080,000 | $22,114,400 | 151.7% |
| IONS | March 31, 2025 | 595,000 | $20,801,200 | 98.5% |
| CYTK | June 30, 2026 | 300,000 | $19,773,000 | -9.1% |
| UPB | March 31, 2026 | 720,000 | $19,548,000 | -22.7% |
| WST | June 30, 2026 | 75,000 | $18,798,000 | -1.7% |
| RARE | June 30, 2025 | 500,000 | $18,105,000 | -28.2% |
| LQDA | June 30, 2025 | 1,227,403 | $18,104,194 | 462.0% |
| ESTA | June 30, 2025 | 433,193 | $17,676,440 | 67.2% |
| MDT | Sept. 30, 2025 | 195,000 | $16,998,150 | -3.3% |
| VRNA | June 30, 2025 | 267,627 | $16,991,638 | No longer tracked |
| PRGO | Sept. 30, 2025 | 625,000 | $16,700,000 | -38.0% |
| WGS | June 30, 2026 | 250,000 | $16,055,000 | 18.5% |
| PEN | March 31, 2026 | 50,000 | $15,545,500 | -1.3% |
| LEGN | March 31, 2025 | 475,000 | $15,456,500 | -35.8% |
| AGIO | June 30, 2026 | 450,000 | $15,223,500 | -8.9% |
| ROIV | March 31, 2025 | 1,250,000 | $14,787,500 | 266.8% |
| ENGN | June 30, 2026 | 2,165,000 | $14,743,650 | 3.8% |
| BRKR | Dec. 31, 2025 | 440,000 | $14,295,600 | 25.1% |
| REGN | March 31, 2025 | 20,000 | $14,246,600 | 32.1% |
| REGN | Dec. 31, 2025 | 25,000 | $14,056,750 | 8.5% |
| QURE | Dec. 31, 2025 | 225,000 | $13,133,250 | 106.6% |
| SRPT | June 30, 2025 | 200,000 | $12,764,000 | 14.4% |
| BHVN | Dec. 31, 2025 | 701,700 | $10,532,517 | 26.3% |
| TMO | Sept. 30, 2025 | 25,000 | $10,136,500 | 27.9% |
| A | March 31, 2025 | 75,000 | $10,075,500 | 33.7% |
| INSP | Dec. 31, 2025 | 135,000 | $10,017,000 | -34.2% |
| ARVN | June 30, 2026 | 905,465 | $9,597,929 | 9.9% |
| APLT | Dec. 31, 2025 | 14,250,000 | $8,619,825 | No longer tracked |
| MPLT | June 30, 2026 | 420,000 | $8,538,600 | -68.7% |
| MNMD | March 31, 2026 | 637,000 | $8,529,430 | No longer tracked |
| FULC | June 30, 2026 | 1,100,000 | $8,437,000 | 6.0% |
| ZLAB | March 31, 2025 | 300,000 | $7,857,000 | -28.0% |
| CGON | Dec. 31, 2025 | 175,000 | $7,049,000 | 88.5% |
| TVRD | Dec. 31, 2025 | 167,000 | $6,507,990 | -56.9% |
| VTYX | Dec. 31, 2025 | 2,050,000 | $6,375,500 | No longer tracked |
| GILD | March 31, 2026 | 50,000 | $6,137,000 | 3.9% |
| NTLA | March 31, 2025 | 525,000 | $6,121,500 | 79.0% |
| IMVT | June 30, 2025 | 350,000 | $5,981,500 | 178.4% |
| DBVT | March 31, 2026 | 300,000 | $5,751,000 | -30.5% |
| CADL | June 30, 2026 | 1,125,000 | $5,512,500 | 23.4% |
| GSK | Dec. 31, 2025 | 125,000 | $5,395,000 | 5.5% |
| ITOS | June 30, 2025 | 900,000 | $5,373,000 | No longer tracked |
| TVTX | Sept. 30, 2025 | 355,000 | $5,254,000 | 171.9% |
| MIRM | March 31, 2026 | 66,000 | $5,213,340 | 5.4% |
| GLPG | June 30, 2025 | 200,000 | $5,024,000 | No longer tracked |
| CMRX | March 31, 2025 | 1,400,000 | $4,872,000 | No longer tracked |
| ZBH | Sept. 30, 2025 | 50,000 | $4,560,500 | 0.9% |
| LENZ | March 31, 2026 | 275,000 | $4,400,000 | -47.8% |
| VCYT | June 30, 2026 | 130,687 | $4,209,428 | -29.5% |
| EXAS | Dec. 31, 2025 | 75,000 | $4,103,250 | No longer tracked |
| ESTA | Dec. 31, 2025 | 100,000 | $4,099,000 | -2.0% |
| KOD | Dec. 31, 2025 | 250,000 | $4,092,500 | 43.5% |
| RZLT | March 31, 2026 | 1,686,000 | $3,978,960 | 60.8% |
| GERN | June 30, 2026 | 2,540,000 | $3,784,600 | 21.5% |
| KNSA | June 30, 2025 | 169,864 | $3,772,679 | 181.9% |
| NBIX | Sept. 30, 2025 | 30,000 | $3,770,700 | 9.7% |
| ARQT | Dec. 31, 2025 | 200,000 | $3,770,000 | -13.5% |
| VERV | March 31, 2025 | 645,000 | $3,637,800 | No longer tracked |
| RCUS | Dec. 31, 2025 | 250,000 | $3,400,000 | 26.2% |
| ALLO | March 31, 2025 | 1,500,000 | $3,195,000 | 44.9% |
| TMDX | March 31, 2025 | 50,000 | $3,117,500 | 37.0% |
| GLUE | March 31, 2025 | 425,000 | $2,949,500 | 221.4% |
| STRO | March 31, 2026 | 243,000 | $2,811,510 | -12.6% |
| NVCR | June 30, 2026 | 250,000 | $2,725,000 | 14.9% |
| URGN | June 30, 2026 | 139,079 | $2,500,640 | 25.7% |
| GPCR | March 31, 2026 | 35,000 | $2,434,250 | 5.5% |
| PASG | June 30, 2026 | 305,000 | $2,394,250 | -3.7% |
| ARCT | June 30, 2025 | 211,790 | $2,242,856 | -9.8% |
| BDTX | March 31, 2026 | 870,000 | $2,114,100 | 5.9% |
| TYRA | June 30, 2026 | 54,000 | $2,068,200 | -17.4% |
| BHC | March 31, 2025 | 250,000 | $2,015,000 | 4.9% |
| NGNE | March 31, 2025 | 80,000 | $1,828,800 | 228.3% |
| ACHL | March 31, 2025 | 1,500,000 | $1,710,000 | No longer tracked |
| FATE | March 31, 2026 | 1,725,000 | $1,694,985 | 108.0% |
| VRDN | Sept. 30, 2025 | 100,000 | $1,398,000 | 14.1% |
| LUNG | Dec. 31, 2025 | 830,000 | $1,344,600 | 6.3% |
| ALEC | March 31, 2026 | 755,000 | $1,177,800 | 5.8% |
| RGNX | June 30, 2026 | 108,525 | $909,440 | -8.3% |
| MGNX | June 30, 2026 | 280,000 | $809,200 | -9.6% |
| ATRA | Sept. 30, 2025 | 94,085 | $726,336 | -35.3% |
| ABSI | June 30, 2026 | 232,219 | $696,657 | -17.5% |
| TRAW | Dec. 31, 2025 | 150,000 | $277,500 | -53.9% |
| CNTA | June 30, 2025 | 14,888 | $214,089 | No longer tracked |